Sodium-glucose cotransporter-2 inhibitor
Showing 26 - 50 of >10,000
Epilepsy Trial in Saint Louis (Empagliflozin 25 mg, Placebo)
Recruiting
- Epilepsy
- Empagliflozin 25 mg
- Placebo
-
Saint Louis, MissouriWashington University
Aug 20, 2022
Transthyretin Amyloid Cardiomyopathy Trial in New York (Empagliflozin)
Recruiting
- Transthyretin Amyloid Cardiomyopathy
-
New York, New YorkColumbia University Irving Medical Center / NewYork-Presbyterian
Mar 15, 2022
Diabetes, Cardiovascular Diseases Trial in Singapore (Renin-angiotensin-aldosterone system inhibitors, Beta blocker, SGLT2
Recruiting
- Diabetes Mellitus
- Cardiovascular Diseases
- Renin-angiotensin-aldosterone system inhibitors
- +2 more
-
Singapore, SingaporeSingapore General Hospital (SGH)
Apr 28, 2021
(NIS) on Sodium-glucose Co-transporter-2 Inhibitors Use in
Not yet recruiting
- Diabetes Mellitus, Type 2
- Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
- (no location specified)
May 22, 2023
Heart Failure Trial in Denmark (Digital letter)
Recruiting
- Heart Failure
- Digital letter
-
Copenhagen, Denmark
- +4 more
Jun 5, 2023
IgA Nephropathy, Immunoglobulin A Nephropathy Trial (Atrasentan, Placebo)
Not yet recruiting
- IgA Nephropathy
- Immunoglobulin A Nephropathy
- Atrasentan
- Placebo
- (no location specified)
Apr 27, 2023
Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in
Completed
- Diabetes Mellitus, Type 2
- Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
- Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
-
Gentofte, Denmark
- +12 more
Jan 18, 2022
![](/image/sponsor/university_of_campania_"luigi_vanvitelli")
GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Type 2
Recruiting
- Diabetes Mellitus, Type 2
- Myocardial Infarction
- PCI
-
Naples, ItalyCelestino Sardu
Aug 31, 2023
Nephropathy, Diabetic Nephropathies, Diabetes, Type 1 Trial in Herlev (Sotagliflozin, Placebo)
Not yet recruiting
- Nephropathy
- +6 more
- Sotagliflozin
- Placebo
-
Herlev, DenmarkSteno Diabetes Center Copenhagen
Nov 19, 2023
Atrial Fibrillation Trial (Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor, Rhythm control and anticoagulation)
Not yet recruiting
- Atrial Fibrillation
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Rhythm control and anticoagulation
- (no location specified)
Aug 14, 2023
CHF Trial in Moscow (Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin,
Recruiting
- Congestive Heart Failure
- Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
-
Moscow, Russian Federation
- +1 more
Mar 15, 2022
Metabolic Associated Fatty Liver Disease Trial (dapagliflozin (Forxiga))
Not yet recruiting
- Metabolic Associated Fatty Liver Disease
- dapagliflozin (Forxiga)
- (no location specified)
Mar 13, 2023
Healthy Volunteers Trial run by the NIDDK (Placebo, Canagliflozin)
Completed
- Healthy Volunteers
- Placebo
- Canagliflozin
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Glomerulonephritis, Proteinuria Trial in Cairo (Empagliflozin 25 MG, )
Completed
- Glomerulonephritis
- Proteinuria
- Empagliflozin 25 MG
- placebo
-
Cairo, EgyptCairo university hospitals
Mar 7, 2022
Diabetic Retinopathy Trial in Cairo (Dapagliflozin 10mg Tab plus another oral hypoglycemic agent, Two oral hypoglycemic agents
Recruiting
- Diabetic Retinopathy
- Dapagliflozin 10mg Tab plus another oral hypoglycemic agent
- Two oral hypoglycemic agents other than dapagliflozin
-
Cairo, EgyptInternal medicine and endocrinology department, Ain-shams univer
Jun 9, 2022
Kidney Transplant Recipients Trial in Toronto (Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL)
Not yet recruiting
- Kidney Transplant Recipients
- Dapagliflozin 10 MG
- Semaglutide, 1.0 mg/mL
-
Toronto, Ontario, CanadaToronto General Hospital
Jul 6, 2023
Deformation Imaging by Strain in Chronic Heart Failure Over
Recruiting
- Sodium-GLucose coTransporter-2 Inhibitors
- Heart Failure With Reduced Ejection Fraction
- Sodium-GLucose coTransporter-2 inhibitors
-
Siena, ItalyUOC Diagnostica Cardiovascolare, AOU Senese Policlinico Le Scott
May 5, 2022
Acute Heart Failure Trial in Cairo (Dapagliflozin 10mg Tab)
Active, not recruiting
- Acute Heart Failure
- Dapagliflozin 10mg Tab
-
Cairo, EgyptKasr Al-Ainy Medical School
Aug 24, 2023
Myocardial Ischemia Trial (Dapagliflozin 10mg Tab, Placebo)
Not yet recruiting
- Myocardial Ischemia
- Dapagliflozin 10mg Tab
- Placebo
- (no location specified)
Feb 27, 2023
SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac
Recruiting
- Coronary Artery Disease
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
-
Shah Alam, Selangor, MalaysiaInstitute for Clinical Research, National Institutes of Health,
Nov 9, 2023
Heart Failure, Reduced Ejection Fraction Heart Failure Trial in Damanhur (Empagliflozin 10 MG, Dapagliflozin 10 MG)
Recruiting
- Heart Failure
- Reduced Ejection Fraction Heart Failure
- Empagliflozin 10 MG
- Dapagliflozin 10 MG
-
Damanhūr, Elbehairah, EgyptDamanhour Teaching Hospital, General Organization for Teaching H
Oct 3, 2023
Obesity, Dapagliflozin Adverse Reaction, Weight Loss Trial (Dapagliflozin 10mg Tab)
Not yet recruiting
- Obesity
- +3 more
- Dapagliflozin 10mg Tab
- (no location specified)
Aug 14, 2023
Diabetic Nephropathy Type 2 Trial (Empagliflozin 25 MG, Enalapril Maleate 20 mg)
Not yet recruiting
- Diabetic Nephropathy Type 2
- Empagliflozin 25 MG
- Enalapril Maleate 20 mg
- (no location specified)
May 9, 2022
Glucose Metabolism Disorders, Diabetes, Type 2, Hypoglycemic Agents Trial in Karachi (Empagliflozin 10 MG,
Recruiting
- Glucose Metabolism Disorders
- +3 more
- Empagliflozin 10 MG
- Insulin+Metformin+DPP4 inhibitor (DPP4I)
-
Karachi, PakistanSINA Shireen Jinnah colony
Nov 28, 2023
Aortic Valve Stenosis Trial in Strasbourg (Myocardium biopsy)
Not yet recruiting
- Aortic Valve Stenosis
- Myocardium biopsy
-
Strasbourg, FranceHôpitaux Universitaires de Strasbourg
Apr 13, 2023